Compare AstraZeneca plc (AZN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Teladoc Health Inc — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while Teladoc Health Inc trades at $9.27 (market cap $1.67B). The key difference: AstraZeneca plc is far larger — about 151.6× Teladoc Health Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| AZN | TDOC | |
|---|---|---|
Market Cap | $253.13B | $1.67B |
Sector | Health | Health |
52-Week High | $209.48 | $9.65 |
52-Week Low | $137.44 | $4.47 |
Enterprise Value | $279.37B | $1.96B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
TDOC trades at $9.65, up 3.99% with bullish technical signals but mixed fundamentals. Revenue remains stable around $2.5B, yet net losses persist with a -6.81% margin. Analyst consensus is cautious with 64% hold ratings, though recent partnerships like Walmart's Better Care show growth potential. Cash flow trends indicate significant net outflows, raising liquidity concerns despite a solid gross margin of 69.29%.
Outlook hinges on cost management and partnership execution; risks include sustained losses and high debt. The stock offers speculative upside if profitability improves, but investor patience is required amid competitive pressures and volatile sentiment. Current price near resistance at $10 suggests limited near-term upside without positive earnings surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
